Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA meeting on epinephrine

This article was originally published in The Tan Sheet

Executive Summary

FDA announces a Dec. 5 public meeting to solicit comments on a proposed rule to amend the agency's regulation on the use of ozone-depleting substances in self-pressurized containers to "remove the essential-use designation for oral pressurized metered-dose inhalers containing epinephrine." In addition, the comment period on the proposed rule published in September is being extended to Dec. 19, FDA says (1"The Tan Sheet" Sept. 24, 2007, p. 7). Meeting attendees must register by Nov. 23, according to the agency...

You may also be interested in...

Primatene Mist To Be Unavailable After 2010 – Proposed Rule

Wyeth will allow its epinephrine-containing Primatene Mist metered-dose inhaler to be phased out of the market after 2010, rather than reformulating to comply with an FDA proposed rule published in the Sept. 20 Federal Register

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts